Efficacy and Safety of Sulindac on Colorectal Polyps: A Systematic_West China Medical Journal

Authors：

LIU Ruming ^1,2 , WU Bin ^1,2 ,  TANG Yao ¹

Department of Pharmacy, West China Hospital; 2. West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

TANG Yao, Email: lrm5218@yahoo.cn

Keywords：

結直腸息肉; 舒林酸; 有效性; 不良反應; 系統評價

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　評價舒林酸治療結直腸息肉的有效性和安全性。　方法　計算機檢索PubMed、Cochrane Iibrary、Embase、SCI、CNKI、萬方、維普、CBM數據庫。按Cochrane系統評價的方法評價納入研究質量，并進行Meta分析。　結果　共納入7個隨機對照試驗（RCT），共235例患者。Meta分析結果顯示舒林酸治療腺瘤性息肉病（FAP）在有效率、息肉消失率方面與安慰劑比較，差異無統計學意義（P gt;0.05）；治療散發性結腸腺瘤性息肉病（SCAP）在有效率、息肉消失率、腺瘤直徑變化方面與安慰劑比較，差異有統計學意義（P lt;0.05）；舒林酸的不良反應多為消化道癥狀，與安慰劑比較差異有統計學意義（P lt;0.05）。　結論　系統評價結果顯示舒林酸對于家族性FAP的療效尚不確切，而對SCAP有一定的療效。
【關鍵詞】結直腸息肉；舒林酸；有效性；不良反應；系統評價
【Abstract】　Objective　 To assess the efficacy and safety of sulindac on colorectal polyps.　Methods　 The literatures were searched from several databases including PubMed,Cochrane Iibrary,SCI,CNKI,Wanfang,VIP,and CBM. The quality of the researches was evaluated according to Cochrane systematic reviews, and the Meta analysis was performed.　Results　 Seven RCT were enrolled with a total of 235 patients. Meta analysis showed that there was no significant difference in the effective rate and polyps disappearance rate of FAP between the two groups (P gt;0.05). There were significant differences in the effective rate, polyps disappearance rate and size of adenomas between the two groups (P lt;0.05); the most common adverse event was the symptoms of digestive tract which differed much from that in the placebo group (P lt;0.05).　Conclusion　 The therapeutic effect of sulindac on FAP is not sure, but it is effective on SCAP.

Citation： LIU Ruming,WU Bin,TANG Yao. Efficacy and Safety of Sulindac on Colorectal Polyps: A Systematic. West China Medical Journal, 2011, 26(1): 81-84. doi: Copy

1.	吳在德, 吳肇漢. 外科學[M]. 6版. 北京: 人民衛生出版社, 2006: 510-515.
2.	Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer [J]. Prog Exp Tumor Re, 2003, 37(1): 1-24.
3.	Cerdan FJ, Torresmelero J, Martinez S, et al. Treatment of familiar adenomatous polyposis-coli with sulindac[J]. Revista Espanola De Enfermedades Digestivas, 1995, 87(8): 574-576.
4.	Cruzcorrea M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study[J]. Gastroenterology, 2002, 122(3): 641-645.
5.	Hixson LJ, Earnest DL, Fennerty MB, et al. NSAID effect on sporadic colon polyps[J]. Am J Gastroenterol, 1993, 88(10): 1652-1656.
6.	Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy[J]. Gastroenterology, 1994, 107(3): 854-857.
7.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 0. 1 [updated September 2008]. The Cochrane Collaboration, 2008.
8.	Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis[J]. N Engl J Med, 1993, 328(18): 1313-1316.
9.	Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis[J]. Br J Surg, 1993, 80(12): 1618-1619.
10.	Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac[J]. N Engl J Med, 2002, 346(14): 1054-1059.
11.	Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps[J]. Gastroenterology, 1995, 108(4): 1083-1087.
12.	錢躍清, 呂愈敏, 葉嗣懋. 舒林酸治療散發性結直腸腺瘤的臨床研究[J]. 中華消化雜志, 2001, 21(12): 710-712.
13.	賈道全, 武衛國, 羅成福, 等. 舒林酸與內鏡下高頻電切治療結直腸腺瘤的轉歸分析[J]. 中華消化內鏡雜志, 2003, 20(2): 125-126.
14.	陳和平, 韓盛璽, 徐剛, 等. 舒林酸治療散發性結腸腺瘤性息肉的機制研究[J]. 中國醫刊, 2008, 43(9): 51-53.

1. 　吳在德, 吳肇漢. 外科學[M]. 6版. 北京: 人民衛生出版社, 2006: 510-515.
2. 　Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer [J]. Prog Exp Tumor Re, 2003, 37(1): 1-24.
3. 　Cerdan FJ, Torresmelero J, Martinez S, et al. Treatment of familiar adenomatous polyposis-coli with sulindac[J]. Revista Espanola De Enfermedades Digestivas, 1995, 87(8): 574-576.
4. 　Cruzcorrea M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study[J]. Gastroenterology, 2002, 122(3): 641-645.
5. 　Hixson LJ, Earnest DL, Fennerty MB, et al. NSAID effect on sporadic colon polyps[J]. Am J Gastroenterol, 1993, 88(10): 1652-1656.
6. 　Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy[J]. Gastroenterology, 1994, 107(3): 854-857.
7. 　Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 0. 1 [updated September 2008]. The Cochrane Collaboration, 2008.
8. 　Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis[J]. N Engl J Med, 1993, 328(18): 1313-1316.
9. 　Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis[J]. Br J Surg, 1993, 80(12): 1618-1619.
10. 　Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac[J]. N Engl J Med, 2002, 346(14): 1054-1059.
11. 　Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps[J]. Gastroenterology, 1995, 108(4): 1083-1087.
12. 　錢躍清, 呂愈敏, 葉嗣懋. 舒林酸治療散發性結直腸腺瘤的臨床研究[J]. 中華消化雜志, 2001, 21(12): 710-712.
13. 　賈道全, 武衛國, 羅成福, 等. 舒林酸與內鏡下高頻電切治療結直腸腺瘤的轉歸分析[J]. 中華消化內鏡雜志, 2003, 20(2): 125-126.
14. 　陳和平, 韓盛璽, 徐剛, 等. 舒林酸治療散發性結腸腺瘤性息肉的機制研究[J]. 中國醫刊, 2008, 43(9): 51-53.

West China Medical Journal

Efficacy and Safety of Sulindac on Colorectal Polyps: A Systematic

Abstract Full text Figures/Tables Video References Cited by

Format

Content